Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 152 participants.

Also called NCT01513369

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 152 participants (planned count) (from the registry)
Sponsor
GWT-TUD GmbH (from the registry)
Registry
  • NCT NCT01513369
  • EudraCT 2011-005224-18
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01513369. Randomized; single masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2018-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ferric Carboxymaltose in Type 2 Diabetes Mellitus (T2DM) Patients With Iron Deficiency
Acronym
CLEVER
Condition
Type 2 Diabetes Mellitus
Condition
Iron Deficiency
Intervention (Drug)
ferric carboxymaltose
Intervention (Drug)
NaCl (0,9%)
Lead sponsor
GWT-TUD GmbH (class: other)
Collaborator
Vifor Pharma (class: industry)

Record details

Record id
cardio:ct-nct01513369
Content hash
521678796ab2088598cf3150a8aad4347774e0701831096fd7f05d5ebd9f8043